MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Northland Capmk issued their Q1 2025 earnings estimates for shares of MiMedx Group in a research note issued on Friday, December 27th. Northland Capmk analyst C. Byrnes expects that the company will post earnings of $0.05 per share for the quarter. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group's Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.
Separately, StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MiMedx Group presently has a consensus rating of "Buy" and an average target price of $12.00.
Get Our Latest Stock Report on MDXG
MiMedx Group Price Performance
Shares of MDXG stock traded up $0.06 during trading hours on Monday, hitting $9.48. 633,491 shares of the company's stock were exchanged, compared to its average volume of 749,037. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The firm has a market cap of $1.39 billion, a P/E ratio of 17.24 and a beta of 1.98. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average of $8.35 and a two-hundred day moving average of $7.17.
Hedge Funds Weigh In On MiMedx Group
A number of institutional investors have recently bought and sold shares of the company. Blue Trust Inc. purchased a new stake in MiMedx Group in the third quarter valued at $30,000. Point72 Asset Management L.P. acquired a new stake in shares of MiMedx Group during the 2nd quarter worth about $40,000. Point72 DIFC Ltd raised its holdings in MiMedx Group by 127.6% in the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after buying an additional 4,275 shares during the period. Entropy Technologies LP acquired a new position in MiMedx Group in the third quarter valued at about $64,000. Finally, Quest Partners LLC purchased a new position in MiMedx Group during the second quarter worth about $81,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Featured Stories
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
